Physician profile
Glenn Keiper
NPI 1093732653
$153,369.54
in general payments reported to CMS, 2019-2025
11 companies · $59.66 in 2025
The $59.66 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $33K · 2021: $31K · 2022: $34K · 2023: $19.25 · 2024: $1,197 · 2025: $59.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,000 · Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,000.00 |
| Food and Beverage | $275.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spineart Sa | $122,342.00 | 2019-2022 | |
| Spineart USA INC | $19,069.73 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $9,626.71 | 2019-2020 | |
| Si-Bone, INC. | $1,287.49 | 2022-2025 | |
| Abbott Laboratories | $263.30 | 2020-2025 | Proclaim, Eterna |
| Spine Wave, INC. | $256.20 | 2019 | |
| Titan Spine, LLC | $175.30 | 2019 | |
| Curiteva, INC. | $113.61 | 2021 | |
| Intrinsic Therapeutics | $106.50 | 2022 | |
| Surgalign Spine Technologies, INC. | $78.66 | 2020-2021 | |
| Nalu Medical, INC. | $50.04 | 2024 | Nalu Neurostimulation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Keiper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.